Prescription Fills for Semaglutide Products by Payment Method-Reference-Cited by-同舟云学术

Prescription Fills for Semaglutide Products by Payment Method

Published:2024-08-02 Issue:8 Volume:5 Page:e242026
ISSN:2689-0186
Container-title:JAMA Health Forum
language:en
Short-container-title:JAMA Health Forum

Author:

Scannell Christopher¹²,Romley John¹³⁴,Myerson Rebecca¹⁵,Goldman Dana¹³,Qato Dima M.¹⁴

Affiliation:

1. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles

2. Los Angeles Area Health Service Research Training Program, Fielding School of Public Health, University of California, Los Angeles

3. Price School of Public Policy, University of Southern California, Los Angeles

4. Program on Medicines and Public Health, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles

5. Department of Population Health Sciences, University of Wisconsin, Madison

Abstract

This cross-sectional study examines trends in US prescription fills for semaglutide products by payment method between January 2021 and December 2023.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jama-health-forum/articlepdf/2821688/scannell_2024_ld_240016_1722440926.42896.pdf

Reference6 articles.

1. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.;Sattar;Lancet Diabetes Endocrinol,2021

2. Medicare Part D coverage of antiobesity medications—challenges and uncertainty ahead.;Baig;N Engl J Med,2023

3. State coverage and reimbursement of antiobesity medications in Medicaid.;Liu;JAMA,2024

4. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US.;Eberly;JAMA Health Forum,2021

5. Medications containing semaglutide marketed for type 2 diabetes or weight loss. US Food and Drug Administration. 2024. Accessed February 10, 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss